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Abstract: Problem statement: Drug resistance in Tuberculosis (TB) is an emerging problem that 
adversely affects patient outcome and public health in the developing world. Although much of 
tuberculosis care is provided by the private sector in India, the magnitude of drug resistance in TB 
in the private sector is not well described. The present study was carried out to determine the 
resistance pattern of tuberculosis in patients attending a large tertiary care hospital in South India. 
Approach: Anti-tuberculosis resistance patterns of all Mycobacterium tuberculosis (M.tb) isolates in a 
tertiary care referral hospital from January 2010 to December 2010 were studied retrospectively. Isolates 
were grown in MB/BacT automated liquid culture system. Sensitivities to various anti-tuberculosis drugs 
were done by the proportion method on Lowenstein-Jensen (L-J) media. Results: During the study 
period, sensitivity reports for 50 Mycobacterium isolates were available.14 (28%) of the isolates were 
multi-drug resistant isolates (resistant to both isoniazid and rifampicin). Isolated resistance to isoniazid, 
rifampicin, ethambutol, pyrazinamide and streptomycin were 42, 32, 28, 48.28 and 44% respectively. 
Moxifloxacin was tested against only 12 tuberculosis isolates and was uniformly sensitive against all 
isolates tested. Conclusion: Nearly one third of M.tb isolates in a private sector tertiary care hospital 
were multi-drug resistant. Isolated resistance to ethambutol was the lowest among the first line anti-
tuberculosis drugs and resistance to moxifloxacin was not seen in this study. Even allowing for referral 
bias, our results suggest that tertiary care hospitals which see complicated tuberculosis patients should 
routinely ask for susceptibility tests whenever M.tb is cultured.  
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INTRODUCTION 
 
  Drug  resistant  Tuberculosis  (TB)  is  a  not  a  new 
phenomenon and has been known from the time when 
drugs  were introduced for the treatment of TB. Drug 
resistant  TB  adversely  affects  patient  outcome  and 
public  health  in  the  developing  world.  The  past  two 
decades have seen the global appearance of Multidrug-
Resistant  Tuberculosis  (MDR-TB)  (Frieden  et  al., 
1993;  Robert  et  al.,  2003),  followed  by  Extensively 
Drug-Resistant  Tuberculosis  (XDR-TB)  (Shah  et  al., 
2007)  and  of  late  strains  those  are  resistant  to  all 
antituberculosis drugs (Velyati et al., 2009). Data from 
the  published  literature  are  insufficient  to  indicate 
whether  the  incidence  of  Multidrug-Resistant  (MDR) 
TB  is  rising  or  falling  globally  as  many  national 
programs  are  failing  to  diagnose  MDR  tuberculosis. 
Globally, only 30, 000 cases of MDR-TB were reported 
to  World  Health  Organization  (WHO)  in  2008, 
compared to the estimate of 440,000 cases (7% of the 
estimated total). The WHO/IUALTD Global project on 
Anti-tuberculosis  Drug  Resistance  Surveillance 
recorded  considerable  variation  in  the  prevalence  of 
drug  resistance  among  35  countries  in  5  different 
continents (Velyati et al., 2009).  
  Drug susceptibility testing in India is not routinely 
performed and public health laboratory infrastructure is 
limited and poorly equipped to cope with large scale 
testing. Most of the published reports on tuberculosis 
drug resistance in India came from surveillance studies 
conducted in outpatient settings under Revised National 
TB  Control  Program  (RNTCP)  (Paramasivan  et  al., 
2002;  2000).  However  a  substantial  proportion  of 
patients with tuberculosis or drug resistant tuberculosis 
seek  care  with  private  care  providers  International 
Institute  of  Population  Sciences  IIPS,  2007.  In 
countries  with  high  burden  of  MDR  tuberculosis, 
more  than  half  of  all  sales  of  first  line  anti-
tuberculosis drugs occur in the private care sector and 
the proportion is even higher for sales of second-line Am. J. Infect. Dis., 7 (4): 104-106, 2011 
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drugs  (GATBDD,  2007).  The  information  on  anti 
tuberculosis  drug  resistance  from  private  health  care 
sector  is  localized  within  certain  regions  of  India 
(Rodrigues et al., 2006). The aim of the present study 
was to describe the pattern of drug resistance among 
M.tb isolates in patients attending a private tertiary care 
referral hospital in South India. 
 
MATERIALS AND METHODS 
 
  This  was  a  retrospective,  descriptive,  laboratory 
based study of tuberculosis isolates  from the patients 
attending  a  600  bed  tertiary  care  hospital  located  in 
Chennai,  South  India  between  January  2010  and 
December 2010. 
  Isolates were grown in MB/BacT automated liquid 
culture system. Sensitivities to various anti-tuberculosis 
drugs  were  done  by  the  proportion  method  on 
Lowenstein-Jensen (L-J) media.  
  The  following  definition  of  resistance  was 
followed in defining the isolates: 
 
·  Multidrug-resistance:  resistance  to  both  isoniazid 
(H) and rifampicin (R) 
·  Monoresistance: resistance to only one drug 
·  Polyresistance:  resistance  to  two  or  more  drugs 
excluding HR resistance 
·  Drug sensitive: absence of resistance to any of 
the drugs 
 
  The ethical committee of the hospital gave ethical 
clearance for this study.  
 
RESULTS 
 
  During the study period, drug susceptibility results 
were available for 50 of the M.tb isolates. Of the 50 
isolates  14  (28%)  were  drug  sensitive  isolates 
(susceptible to all the anti-tuberculosis drugs) and 14 
were  MDR  isolates.  Poly-resistant  isolates  were  the 
predominate  isolates  (15/50-30%)  in  this  study  and 
mono-resistant  isolates  were  seen  only  in  7  isolates 
(14%),  but  none  of  the  isolates  were  extremely  drug 
resistant (XDR) TB isolates in this study. 
  As shown in Table 1 among the individual first line 
drugs the resistance rates were 48.28, 44, 42, 32 and 
28%  for  pyrazinamide,  streptomycin,  isoniazid, 
rifampicin  and  ethambutol  respectively.  For  the 
second  line  drugs  resistance  rate  were  32.26%  for 
ethionamide  and  17.22%  for  amilkacin. 
Moxifloxacin  was  the  only  drug  sensitive 100% of 
the time (13/13 of the isolates) in this study. 
Table 1: Drug susceptibility patterns of Mycobacterium tuberculosis 
isolates to first and second line drugs 
Drugs  Sensitive  Resistant  Resistance rate 
(Total no isolates tested)   (N)   (N)   (%) 
Isoniazid (50)  29  21  42.00 
Rifampicin (50)  34  16  32.00 
Pyrazinamide (29)  15  14  48.28 
Ethambutol (50)  36  14  28.00 
Stretomycin(50)  28  22  44.00 
Amikacin (29)  24  5  17.22 
Etionamide (37)  21  16  32.26 
Moxifloxacin (12)  12  0  0.00 
 
DISCUSSION 
 
  Our  study  found  a  high  prevalence  of  drug 
resistance to at least one anti-tuberculosis drug (72%) 
and an MDR-TB prevalence of 28% in patient attending 
our tertiary care hospital in South India. The estimated 
prevalence of MDR-TB in our study was less than in 
other study conducted in a tertiary hospital in Mumbai 
(Almedia et al., 2003) (resistance to any one drug 80% 
and  MDR-TB  51%).  However  it  was  substantially 
higher  than  rates  found  in  a  number  of  surveillance 
studies  conducted  in  RNTCP  programs  (resistance  to 
any  one  drug  was  21-46%  and  MDR-TB  2.4-17.4%) 
(Chandrasekaran  et  al.,  1990;  Anuradha  et  al.,  2006; 
Ramachandran et al., 2009). Bias in the selection and 
differences  in  the  methodology  may  explain  such 
variations in the prevalence rates. 
  The  resistance  rates  noticed  in  our  study  to 
isoniazid and rifampicin were 42 and 32% respectively. 
Previous surveillance studies conducted in the state of 
Gujarat (Ramachandran et al., 2009) showed that the 
frequency of INH and rifampicin resistance were in the 
range of 11-37% for INH and 2.5%-18% for rifampicin 
and the study conducted by the Deodhar et al. (1999) in 
Bombay showed similar rates to our study (H-30.41%, 
R-  58.55%).  This  high  rate  of  INH  and  rifampicin 
resistance may be due to wide spread use of these drugs 
in first line treatment of patients and possibly irregular 
and  inadequate  dosing  of  the  drug.  In  our  study,  the 
highest (48.28%) resistance among the first line drugs 
was  found  against  pyrazinamide.  PZA  susceptibility 
testing  is  not  routinely  recommended  as  it  acts  at  a 
lower pH where bacteria do not grow, but for special 
reasons it can be performed in small number of isolates 
(UNION/WHO, 1994; Mitchison, 2005). In our study 
ethambutol  had  the  lowest  resistance  rate  among  the 
first  line  anti-TB  drugs  (28%),  similar  to  previous 
surveillance studies (1.9-10.2%). This advantage should 
be  exploited  while  constructing  an  effective  empiric 
second line regimen for MDR-TB. 
  Among the second line drugs, ethionamide has got 
maximum  resistance  in  our  study  with  32.26%,  a Am. J. Infect. Dis., 7 (4): 104-106, 2011 
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prevalence  rate  similar  to  studies  conducted  in  the 
RNTCP  (25-40.5%)  (Ramachandran  et  al.,  2009). 
Resistance  to  ethionamide  is  difficult  to  interpret 
because  of  technical  reasons  (Mitchison,  2005).  In 
addition there may be cross-resistance with INH due to 
a mutation in the inhA gene. Moxifloxacin is the only 
drug that retained 100% susceptibility in this study; no 
other  studies  in  India  tested  this  drug.  This  100% 
susceptibility seen in our study could be due to very 
limited use of this drug in both the private sector and in 
national  programs  due  to  its  high  cost.  Resistance  to 
streptomycin  was  much  higher  when  compared  to 
amikacin in this study (44 Vs 17.22%). Streptomycin 
resistance is a concern as it is an essential component of 
category II DOTS regimen. 
  Our study has limitations. Clearly there may be a 
referral bias towards sicker patients and relapses of TB 
in  a  referral  hospital.  Patients’  clinical  data,  drug 
exposure history and outcomes were not analyzed.  
 
CONCLUSION 
 
  In  conclusion  we  found  that  up  to  28%  of 
patients in private settings may have MDR-TB. We 
recommend  routinely  doing  mycobacterial  cultures 
on  clinical  samples  from  all  patients  with  TB  and 
drug-susceptibility  testing  on  all  isolates  of  M.tb. 
There is clearly a need to further study anti-TB drugs 
resistance in hospital based TB patients from private 
health care institutions. 
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